University of South Florida, Tampa, FL 33618, USA.
J Card Fail. 2009 Oct;15(8):651-7. doi: 10.1016/j.cardfail.2009.04.011. Epub 2009 Jun 27.
One of the recent advances in the treatment of breast cancer is trastuzumab. However, a major side effect of this medication is cardiomyopathy. Our objective was to determine the incidence of trastuzumab-induced cardiomyopathy and the rate of discontinuation of trastuzumab in a clinical setting.
We retrospectively reviewed the records of all women treated with trastuzumab at the Moffitt Cancer Center between 2003 and 2007. Cardiomyopathy was defined as symptomatic heart failure or a decrease of ejection fraction by >or=10% from baseline or to <50%. Statistical analysis was done with Fisher exact test, t-test test, and Wilcoxon signed rank test. Cardiomyopathy developed in 52 of 156 (33.3%) of patients being treated with trastuzumab. In the adjuvant group, 23 (19.5%) of women permanently or temporarily discontinued therapy secondary to cardiomyopathy.
Cardiomyopathy is a common side effect of trastuzumab that leads to discontinuation of treatment in a significant proportion of patients. Further studies are indicated to establish the ways to predict, prevent, and treat cardiomyopathy to provide patients with maximal therapeutic benefit of trastuzumab.
乳腺癌治疗的最新进展之一是曲妥珠单抗。然而，这种药物的一个主要副作用是心肌病。我们的目的是确定曲妥珠单抗诱导性心肌病的发生率以及曲妥珠单抗在临床环境中的停药率。
我们回顾性地审查了 2003 年至 2007 年间在 Moffitt 癌症中心接受曲妥珠单抗治疗的所有女性的记录。心肌病定义为有症状的心力衰竭或射血分数从基线下降>或= 10%，至<50%。采用 Fisher 确切检验、t 检验和 Wilcoxon 符号秩检验进行统计学分析。在接受曲妥珠单抗治疗的 156 例患者中，有 52 例（33.3%）发生心肌病。在辅助治疗组中，有 23 名（19.5%）女性因心肌病而永久性或暂时停止治疗。
心肌病是曲妥珠单抗的常见副作用，导致相当一部分患者停止治疗。需要进一步研究以确定预测、预防和治疗心肌病的方法，为患者提供曲妥珠单抗的最大治疗益处。
